American Journal of Cancer

, Volume 2, Issue 5, pp 335–347

Promising New Approaches in the Treatment of Advanced Head and Neck Cancer

  • Paul M. Harari
  • Gregory K. Hartig
  • Danny Rischin
  • Lester J. Peters
Review Article


Squamous cell carcinoma (SCC) of the head and neck (H&N) represents a major international health problem. The overwhelming majority of H&N cancers are strongly associated with tobacco use, and the intense global marketing of tobacco products suggests that it is unlikely there will be a decrease in H&N cancer incidence in the near future. Ongoing advances in surgical techniques continue to diminish treatment-related morbidity for patients with advanced disease. New developments in radiation and chemotherapy suggest that nonoperative treatment strategies will increasingly accomplish effective disease control, particularly with the refinement of concurrent chemoradiotherapy regimens and the use of new molecular agents which modulate H&N tumor growth. In this article, we highlight selected advances in surgery, radiation, and chemoradiation, which hold particular promise for the future of H&N cancer therapy.

The evolution of surgical techniques includes the increasing use of selective neck dissection, the use of conservation techniques in the management of selected laryngeal and hypopharyngeal tumors, the use of free tissue transfer for optimal reconstruction and the increased availability of expertise in combined surgical approaches for tumors of the skull base.

Altered radiation fractionation has evolved to a mature state of knowledge in recent years based primarily on clinical trials performed in patients with advanced H&N cancer. A major current challenge involves how to best interdigitate optimal radiation fractionation with concurrent chemotherapy regimens in H&N cancer.

Among a series of new molecular agents under active investigation in H&N cancer, two specific examples with high promise are discussed, which exploit tumor hypoxia (tirapazamine) and overexpression of the epidermal growth factor receptor (EGFR inhibitors), respectively.

These and other stepwise advances are contributing to the gradual reduction in global mortality rates for H&N cancer patients observed over the last decade, as well as to diminishing the adverse impact on patient quality of life that commonly accompanies treatment for this complex tumor site.


  1. 1.
    Forastiere A, Koch W, Trotti A, et al. Medical progress: head and neck cancer. N Engl J Med 2001; 345(26): 1890–900PubMedCrossRefGoogle Scholar
  2. 2.
    Bocca E, Pignataro O, Oldini C, et al. Functional neck dissection: an evaluation and review of 843 cases. Laryngoscope 1984; 94(7): 942–5PubMedCrossRefGoogle Scholar
  3. 3.
    Cheng PT, Hao SP, Lin YH, et al. Objective comparison of shoulder dysfunction after three neck dissection techniques. Ann Otol Rhinol Laryngol 2000; 109 (8 Pt 1): 761–6PubMedGoogle Scholar
  4. 4.
    Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 1990; 160(4): 405–9PubMedCrossRefGoogle Scholar
  5. 5.
    Dayman GL, Frank DK. Selective neck dissection of anatomically appropriate levels is as efficacious as modified radical neck dissection for elective treatment of the clinically negatice neck in patients with squamous cell carcinoma of the upper respiratory and digestive tracts. Arch Otolaryngol Head Neck Surg 1998; 124(3): 348–52Google Scholar
  6. 6.
    Byers RM. Modified neck dissection: a study of 967 cases from 1970 to 1980. Am J Surg 1985; 150(4): 414–21PubMedCrossRefGoogle Scholar
  7. 7.
    Robbins KT, Atkinson JL, Byers RM, et al. The use and misuse of neck dissection for head and neck cancer. J Am Coll Surg 2001; 193(1): 91–102PubMedCrossRefGoogle Scholar
  8. 8.
    Buckley JG, Feber T. Surgical treatment of cervical node metastases from squamous carcinoma of the upper aerodigestive tract: evaluation of the evidence for modifications of neck dissection. Head Neck 2001; 23(10): 907–15PubMedCrossRefGoogle Scholar
  9. 9.
    Laccourreye H, Menard M, Fabre A, et al. Partial supracricoid laryngectomy: technics, indications, and results. Ann Otolaryngol Chir Cervicofac 1987; 104(3): 163–73PubMedGoogle Scholar
  10. 10.
    Iro H, Waldfahrer F, Altendorf-Hofman A, et al. Transoral laser surgery of supraglottic cancer: follow-up of 141 patients. Arch Otolaryngol Head Neck Surg 1998; 124(11): 1245–50PubMedGoogle Scholar
  11. 11.
    Miyamato RC, Gleich LL, Biddinger PW, et al. Esthesioneuroblastoma and sinonasal carcinoma: impact of histologic grading and clinical staging on survival and prognosis. Laryngoscope 2000; 110(8): 1262–5CrossRefGoogle Scholar
  12. 12.
    Panje WR, Sadeghi N. Endoscopic and electroporation therapy of paranasal sinus tumors. Am J Rhinol 2000; 14(3): 187–91PubMedCrossRefGoogle Scholar
  13. 13.
    Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332(7): 429–35PubMedCrossRefGoogle Scholar
  14. 14.
    Thames HD, Hendry JH. Fractionation in radiotherapy. Philadelphia (PA): Taylor and Francis, 1987Google Scholar
  15. 15.
    Peters LJ, Ang KK, Thames Jr HD. Accelerated fractionation in the radiation treatment of head and neck cancer: a critical comparison of different strategies. Acta Oncol 1988; 27(2): 185–94PubMedCrossRefGoogle Scholar
  16. 16.
    Bourhis J, Syz N, Overgaard J, et al. Conventional vs modified fractionated radiotherapy. Meta-analysis based on indervidual patient data [abstract]. 44 American Society for Therapeutic Radiology and Oncology meeting; 2002 Oct 6–10; New Orleans (LA). Int J Rad Oncol Biol Phys 2002; 54(2 Suppl. 1): 71–2CrossRefGoogle Scholar
  17. 17.
    Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48(1): 7–16PubMedCrossRefGoogle Scholar
  18. 18.
    Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44(2): 111–21PubMedCrossRefGoogle Scholar
  19. 19.
    Horiot JC, Le Fur R, N’Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992; 25(4): 231–41PubMedCrossRefGoogle Scholar
  20. 20.
    Overgaard J, Sand Hansen H, Overgaard M, et al. Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck: a randomized multicenter of 5 verus 6 fractions per week: report from the DAHANCA 7 trial [abstract]. Int J Radiat Oncol Biol Phys 1997; 39(2 Suppl.): 106Google Scholar
  21. 21.
    Bourhis J, Lapeyre M, Tortochaux J, et al. Very accelerated versus conventional radiotherapy in HNSCC: results of the GORTEC 94-02 randomized trial [abstract]. Int J Radiat Oncol Biol Phys 2000; 48(3 Suppl.): 2Google Scholar
  22. 22.
    Skladowski K, Maciejewski B, Golen M, et al. Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer: report on 3-year tumour control and normal tissue toxicity. Radiother Oncol 2000; 55(2): 101–10PubMedCrossRefGoogle Scholar
  23. 23.
    Dische S, Saunders M, Barrett A, et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997; 44(2): 123–36PubMedCrossRefGoogle Scholar
  24. 24.
    Poulsen MG, Denham JW, Peters LJ, et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Oncol 2001; 60(2): 113–22PubMedCrossRefGoogle Scholar
  25. 25.
    Ang K, Weber R, Vokes EE, et al. Radiation Therapy Oncology Group. Research Plan 2002–2006. Head and neck cancer committee. Int J Radiat Oncol Biol Phys 2001; 51(3 Suppl. 2): 39–43PubMedGoogle Scholar
  26. 26.
    Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous- cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group: meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355: 949–55PubMedGoogle Scholar
  27. 27.
    Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancar 2000; 88(4): 876–83PubMedCrossRefGoogle Scholar
  28. 28.
    Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338(25): 1798–804PubMedCrossRefGoogle Scholar
  29. 29.
    Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91(24): 2081–6PubMedCrossRefGoogle Scholar
  30. 30.
    Forastiere AA, Berkey B, Maor M, et al. Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, intergroup trial R91-11 [abstract 4]. Proc Am Soc Clin Oncol 2001; 20: 2aGoogle Scholar
  31. 31.
    Bernier J, Domenge C, Eschwege F, et al. Chemo-radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: results of EORTC phase III trial 22931 [abstract]. Int J Radiat Oncol Biol Phys 2001; 51(1 Suppl.): 1CrossRefGoogle Scholar
  32. 32.
    Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiochemotherapy in high-risk SCCA of the head and neck: initial report of RTOG 9501/intergroup phase III trial [abstract 903]. Proc Am Soc Clin Oncol 2002; 21: 206aGoogle Scholar
  33. 33.
    Brockstein B, Haraf DJ, Stenson K, et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 1998; 16(2): 735–44PubMedGoogle Scholar
  34. 34.
    Shin DM, Lippman SM. Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Semin Oncol 1999; 26(1 Suppl. 2): 100–5PubMedGoogle Scholar
  35. 35.
    Schoffski P, Catimel G, Planting AS, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck: results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999; 10(1): 119–22PubMedCrossRefGoogle Scholar
  36. 36.
    Robbins KT, Kumar P, Regine WF, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys 1997; 38(2): 263–71PubMedCrossRefGoogle Scholar
  37. 37.
    Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6(8): 879–85PubMedCrossRefGoogle Scholar
  38. 38.
    Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638–48PubMedCrossRefGoogle Scholar
  39. 39.
    Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38(2): 285–9PubMedCrossRefGoogle Scholar
  40. 40.
    Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41(1): 31–9PubMedCrossRefGoogle Scholar
  41. 41.
    Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996; 6(1): 10–21PubMedCrossRefGoogle Scholar
  42. 42.
    Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993; 67(6): 1163–70PubMedCrossRefGoogle Scholar
  43. 43.
    Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990; 50(24): 7745–9PubMedGoogle Scholar
  44. 44.
    Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993; 53(19): 4633–6PubMedGoogle Scholar
  45. 45.
    von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. J Clin Oncol 2000; 18(6): 1351–9Google Scholar
  46. 46.
    Lee DJ, Trotti A, Spencer S, et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys 1998; 42(4): 811–5PubMedCrossRefGoogle Scholar
  47. 47.
    Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19(2): 535–42PubMedGoogle Scholar
  48. 48.
    Corry J, Rischin D, Smith JG, et al. Radiation with concurrent late chemotherapy intensification (‘chemoboost’) for locally advanced head and neck cancer. Radiother Oncol 2000; 54(2): 123–7PubMedCrossRefGoogle Scholar
  49. 49.
    Garden AS, Glisson BS, Ang KK, et al. Phase I/II trial of radiation with chemotherapy ‘boost’ for advanced squamous cell carcinomas of the head and neck: toxicities and responses. J Clin Oncol 1999; 17(8): 2390–5PubMedGoogle Scholar
  50. 50.
    Pinto H, Le Q, Terris D, et al. Randomized trial of tirapazamine/cisplatin/ fluorouracil versus cisplatin/fluorouracil for organ preservation in advanced resectable head and neck cancer [abstract 904]. Proc Am Soc Clin Oncol 2002; 21: 227aGoogle Scholar
  51. 51.
    Harari PM, Huang S-M, Herbst RS, et al. Molecular targeting of the epidermal growth factor receptor in head and neck cancer. In: Harrison LB, Sessions RB, Hong WK, editors. Chapter 41 Head and neck cancer: a multidisciplinary approach. Philadeiplia (PA): Lippincott Williams & Wilkins, 2003Google Scholar
  52. 52.
    Harari PM, Huang S-M. Cellular and biologic consequences of epidermal growth factor receptor inhibition. Signal 2002; 3(2): 4–9Google Scholar
  53. 53.
    Gill GN, Kawamoto T, Cochet C, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984; 259(12): 7755–60PubMedGoogle Scholar
  54. 54.
    Kawamoto T, Sato JD, Le A, et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 1983; 80(5): 1337–41PubMedCrossRefGoogle Scholar
  55. 55.
    Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19(56): 6550–65PubMedCrossRefGoogle Scholar
  56. 56.
    Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000; 60Suppl. 1: 25–32PubMedCrossRefGoogle Scholar
  57. 57.
    Baselga J. The EGFR as a target for anticancer therapy: focus on cetuximab. Eur J Cancer 2001; 37Suppl. 4: S16–22PubMedCrossRefGoogle Scholar
  58. 58.
    Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001; 28(5 Suppl. 16): 67–79PubMedCrossRefGoogle Scholar
  59. 59.
    Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19(18 Suppl.): 32S–40SPubMedGoogle Scholar
  60. 60.
    Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001; 13(6): 491–8PubMedCrossRefGoogle Scholar
  61. 61.
    Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999; 18(4): 427–36PubMedCrossRefGoogle Scholar
  62. 62.
    Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60Suppl. 1: 15–23PubMedCrossRefGoogle Scholar
  63. 63.
    Huang S-M, Li J, Harari PM. Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy. In: Giaccone G, Schilsky R, Sondel P, editors. Cancer chemotherapy and biological response modifiers annual 19. Amsterdam: Elsevier, 2001: 339–52Google Scholar
  64. 64.
    Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000; 6(9): 1024–8PubMedCrossRefGoogle Scholar
  65. 65.
    Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001; 21(6): 499–512PubMedCrossRefGoogle Scholar
  66. 66.
    Al-Obeidi FA, Lam KS, Noonberg SB, et al. Development of inhibitors for protein tyrosine kinases. Oncogene 2000; 19(49): 5690–701PubMedCrossRefGoogle Scholar
  67. 67.
    Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7(10): 2958–70PubMedGoogle Scholar
  68. 68.
    Levitt ML, Koty PP. Tyrosine kinase inhibitors in preclinical development. Invest New Drugs 1999; 17(3): 213–26PubMedCrossRefGoogle Scholar
  69. 69.
    Dancey JE, Schoenfeldt M. Clinical trials referral resource: epidermal growth factor receptor inhibitors in clinical trials [abstract]. Oncology (Huntingt) 2001; 15(6): 748–58Google Scholar
  70. 70.
    Bonomi P, Perez-Soler R, Chachoua A, et al. A phase II trial of the epidermal growth fector receptor (EGFR) tyrosine-kinase inhibitor (TKI), CP-358,774, following platinum-based chemotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC) [abstract 386]. Clin Cancer Res 2000; 6Suppl. 11: 4554sGoogle Scholar
  71. 71.
    Bundred NJ, Chan K, Anderson NG. Studies of epidermal growth factor receptor inhibition in breast cancer. Endocr Relat Cancer 2001; 8(3): 183–9PubMedCrossRefGoogle Scholar
  72. 72.
    Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19(13): 3267–79PubMedGoogle Scholar
  73. 73.
    Barton J, Blackledge G, Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy. Urology 2001; 58(2 Suppl. 1): 114–22PubMedCrossRefGoogle Scholar
  74. 74.
    Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001; 1(4): 719–32PubMedCrossRefGoogle Scholar
  75. 75.
    Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18(4): 904–14PubMedGoogle Scholar
  76. 76.
    Shin DM, Donate NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7(5): 1204–13PubMedGoogle Scholar
  77. 77.
    Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19(13): 3234–43PubMedGoogle Scholar
  78. 78.
    Mendelsohn J, Shin DM, Donate NJ, et al. A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC) [abstract 1502]. Proc Am Soc Clin Oncol 1999: 18: 389aGoogle Scholar
  79. 79.
    Pfister DG, Aliff TB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): Preliminary evaluation of a new combined-modality paradigm [abstract 1993]. Proc Am Soc Clin Oncol 2003; 22: 495Google Scholar
  80. 80.
    Hong WK, Arquette M, Nabell L, et al. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy [abstract 895]. Proc Am Soc Clin Oncol 2001; 20: 224aGoogle Scholar
  81. 81.
    Burtness B, Li Y, Flood W, et al. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC) [abstract 901]. Proc Am Soc Clin Oncol 2002; 21: 226aGoogle Scholar
  82. 82.
    Cohen RB, Falcey JW, Paulter VJ, et al. Safety profile of the monoclonal antibody (MoAb)IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors [abstract 1862]. Proc Am Soc Clin Oncol 2000; 19: 474aGoogle Scholar
  83. 83.
    Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144(6): 1169–76PubMedCrossRefGoogle Scholar
  84. 84.
    Khazaeli AF, LoBuglio JW, Falcey JW, et al. Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor-positive tumors [abstract 808]. Proc Am Soc Clin Oncol 2000; 19: 207aGoogle Scholar
  85. 85.
    Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7Suppl. 4: 2–8PubMedCrossRefGoogle Scholar
  86. 86.
    Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 2002; 20(9): 2217–9PubMedGoogle Scholar
  87. 87.
    Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29(5 Suppl. 14): 3–9PubMedGoogle Scholar
  88. 88.
    Harari PM, Huang S-M. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427–33PubMedCrossRefGoogle Scholar
  89. 89.
    de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2002; 8(4 Suppl.): S19–26PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Paul M. Harari
    • 1
  • Gregory K. Hartig
    • 2
  • Danny Rischin
    • 3
  • Lester J. Peters
    • 4
  1. 1.Department of Human OncologyUniversity of Wisconsin School of Medicine and Comprehensive Cancer CenterMadisonUSA
  2. 2.Department of SurgeryUniversity of Wisconsin School of Medicine and Comprehensive Cancer CenterMadisonUSA
  3. 3.Division of Hematology Medical OncologyPeter MacCallum Cancer InstituteMelbourneAustralia
  4. 4.Department of Radiation OncologyPeter MacCallum Cancer InstituteMelbourneAustralia

Personalised recommendations